Published in Asian J Androl on December 01, 2008
Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev (2010) 1.41
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol (2012) 0.99
Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev (2014) 0.97
Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β₃ affinity modulation. Br J Cancer (2012) 0.94
GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget (2014) 0.94
An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl (2013) 0.92
KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC Cancer (2012) 0.92
Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets (2013) 0.92
Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS One (2013) 0.91
CD151 in cancer progression and metastasis: a complex scenario. Lab Invest (2013) 0.91
Ganoderic Acid DM: An Alternative Agent for the Treatment of Advanced Prostate Cancer. Open Prost Cancer J (2010) 0.90
The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) (2012) 0.88
Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis (2015) 0.88
Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian J Urol (2010) 0.86
Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells. Mol Carcinog (2012) 0.85
Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82
Current management of prostate cancer: dilemmas and trials. Br J Radiol (2012) 0.81
Quantum dots for multiplexed detection and characterisation of prostate cancer cells using a scanning near-field optical microscope. PLoS One (2012) 0.81
Phorbol ester stimulates ethanolamine release from the metastatic basal prostate cancer cell line PC3 but not from prostate epithelial cell lines LNCaP and P4E6. Br J Cancer (2014) 0.77
Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro. Gene Ther (2015) 0.76
Human Prostate Cancer Hallmarks Map. Sci Rep (2016) 0.75
The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy. J Extracell Vesicles (2015) 0.75
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res (2012) 0.75
Snail mediates invasion through uPA/uPAR and the MAPK signaling pathway in prostate cancer cells. Oncol Lett (2013) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
Cadherin cell adhesion receptors as a morphogenetic regulator. Science (1991) 13.78
Bone resorption by osteoclasts. Science (2000) 11.68
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol (1991) 8.60
A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature (1998) 8.48
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med (1997) 6.39
Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta (1994) 5.81
Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet (1995) 5.77
Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer (2002) 5.57
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res (1986) 5.05
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst (2001) 4.25
Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest (2000) 3.78
Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol (1994) 3.61
Cadherin dysfunction in a human cancer cell line: possible involvement of loss of alpha-catenin expression in reduced cell-cell adhesiveness. Cancer Res (1992) 2.89
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst (1998) 2.83
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50
Beta-catenin mutations in human prostate cancer. Cancer Res (1998) 2.37
Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res (1994) 2.34
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene (2003) 1.96
The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev (1995) 1.84
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res (1996) 1.83
Mechanisms of bone destruction in the development of skeletal metastases. Nature (1976) 1.81
Cancer and bone. Endocr Rev (1998) 1.77
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett (2003) 1.71
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer (2004) 1.66
Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev (1992) 1.58
Role of endothelin-1 in osteoblastic bone metastases. Cancer (2003) 1.54
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res (2002) 1.46
The normal structure and function of CD44 and its role in neoplasia. Mol Pathol (1998) 1.44
Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J Exp Med (1998) 1.43
Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer (2005) 1.42
New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology (1999) 1.41
Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol (1996) 1.31
Expression of CXCR4, the receptor for stromal cell-derived factor-1 on fetal and adult human lympho-hematopoietic progenitors. Eur J Immunol (1999) 1.29
Modulation of venular microvessel permeability by calcium influx into endothelial cells. FASEB J (1992) 1.29
Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis (1995) 1.26
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol (1994) 1.25
How do Rho family GTPases direct axon growth and guidance? A proposal relating signaling pathways to growth cone mechanics. Differentiation (2002) 1.25
Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer (1983) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol (1991) 1.22
Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br J Cancer (2006) 1.21
Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer (1997) 1.21
Cell-cell interactions during transendothelial migration of tumor cells. Microsc Res Tech (1998) 1.20
Downstream effectors of oncogenic ras in multiple myeloma cells. Blood (2002) 1.20
Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum Pathol (1999) 1.20
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol (1985) 1.16
Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. BJU Int (2003) 1.13
Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology (1996) 1.12
Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl (1994) 1.12
Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol (1996) 1.11
Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer (2000) 1.09
Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett (2003) 1.08
Primary prostatic epithelial cell binding to human bone marrow stroma and the role of alpha2beta1 integrin. Clin Exp Metastasis (1997) 1.07
Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol (2001) 1.05
E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer (1999) 1.05
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol (2004) 1.01
Interaction of prostate epithelial cells from benign and malignant tumor tissue with bone-marrow stroma. Prostate (1998) 1.01
Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol (1993) 0.97
Endothelial cell intracellular Ca2+ concentration is increased upon breast tumor cell contact and mediates tumor cell transendothelial migration. Clin Exp Metastasis (1998) 0.93
Paradoxical expression of E-cadherin in prostatic bone metastases. BJU Int (1999) 0.92
Role of alphaII(b)beta3 integrin in prostate cancer metastasis. Prostate (1998) 0.90
Endothelin inhibition: novel therapy for prostate cancer. J Urol (2003) 0.90
The role of the integrin family of adhesion molecules in the development of tumors metastatic to the orbit. Ophthal Plast Reconstr Surg (1997) 0.89
Identification of PECAM-1 in solid tumor cells and its potential involvement in tumor cell adhesion to endothelium. J Biol Chem (1993) 0.89
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol (1992) 0.89
Parathyroid hormone-related peptide: expression in prostate cancer bone metastases. Prostate Cancer Prostatic Dis (2002) 0.88
Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer (2002) 0.87
Tumor-bone interactions in skeletal metastasis. Clin Orthop Relat Res (1995) 0.85
The detection of prostate cells by the reverse transcription-polymerase chain reaction in the circulation of patients undergoing transurethral resection of the prostate. BJU Int (2000) 0.82
Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol (1968) 0.82
Endothelial cell Ca2+ increases upon tumor cell contact and modulates cell-cell adhesion. J Clin Invest (1993) 0.81
Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer. Urology (2002) 0.77
Detection and clearance of prostate cells subsequent to ultrasound-guided needle biopsy as determined by multiplex nested reverse transcription polymerase chain reaction assay. Urology (1998) 0.76
A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood (2004) 2.90
Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate (2002) 1.52
Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate (2007) 1.31
Novel method for the isolation and characterisation of the putative prostatic stem cell. Cytometry A (2003) 1.18
Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers. Stem Cells Dev (2009) 1.17
Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am J Physiol Renal Physiol (2008) 1.16
The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. Faraday Discuss (2004) 1.04
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. Eur Urol (2004) 1.01
Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res (2007) 0.96
AC133+ G0 cells from cord blood show a high incidence of long-term culture-initiating cells and a capacity for more than 100 million-fold amplification of colony-forming cells in vitro. Stem Cells (2004) 0.91
A correlation of FTIR spectra derived from prostate cancer biopsies with gleason grade and tumour stage. Eur Urol (2006) 0.87
SR-FTIR spectroscopy of renal epithelial carcinoma side population cells displaying stem cell-like characteristics. Analyst (2010) 0.82
Whole organ cross-section chemical imaging using label-free mega-mosaic FTIR microscopy. Analyst (2013) 0.81
Copper modulates zinc metalloproteinase-dependent ectodomain shedding of key signaling and adhesion proteins and promotes the invasion of prostate cancer epithelial cells. Mol Cancer Res (2012) 0.77
Classification of fixed urological cells using Raman tweezers. J Biophotonics (2009) 0.76
The molecular staging of prostate cancer. BJU Int (2004) 0.75